Efficacy and safety of Telitacicept in the treatment of recurrent IgA nephropathy after transplantation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400084654

Enrollment

Unknown

Registered

2024-05-22

Start date

2024-06-01

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent IgA nephropathy after transplantation

Interventions

Experimental grou:Conventional treatment+Taetaxel

Control group:Conventional treatment

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1: Adult recipients aged =18 and =65 years old 2: graft biopsy considered recurrence of IgA nephropathy 3: Have received ACEi/ARB standard treatment for at least 12 weeks, and received the maximum tolerated dose 4 weeks before enrollment 4: 24-hour urine protein quantification = 0.75g and =3g 5: time span between 24-hour urine protein quantification = 0.3g and the enrollment is less than 1 year 6: eGFR =35ml/min/1.73m^2

Exclusion criteria

Exclusion criteria: 1: PRA or DSA positive recipients; 2: recipients whose transplanted kidney biopsy shows rejection; 3: Other known causes of proteinuria; 4: ABO-incompatible kidney transplant recipients 5: Multiple organ transplant recipients; 6: Glycated hemoglobin>6.5%; 7: Those who took Tripterygium wilfordii preparations within 1 month before enrollment; 8: Patients with malignant tumor or patients who have been diagnosed with malignant tumor within the past 5 years but have been cured, except treated basal cell carcinoma of the skin, effectively resected squamous cell carcinoma of the skin, colon polyps, or cervical cancer in situ; 9: Pregnant women, lactating women, and men or women who plan to have children during the trial; 10: Those allergic to human biological products; 11: Subjects deemed unsuitable by the researcher;

Design outcomes

Primary

Measure	Time frame
24-hour urinary protein quantification;	—

Secondary

Measure	Time frame
blood protein levels;eGFR;Serum IgA level;Abnormal glycosylation IgA;Serum IgM level;Serum IgG level;	—

Countries

China

Contacts

Public ContactGang Chen

Institute of Organ Transplantation, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University

gchen@tjh.tjmu.edu.cn+86 130 0618 7015

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026